Sale by Laura SeppLorenzino of 5532 shares of Intellia Therapeutics

NTLA Stock  USD 11.82  0.30  2.48%   
About 61% of Intellia Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Intellia Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Intellia Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Intellia Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Intellia Therapeutics Inc officer. General open market or private sale of non-derivative or derivative security

Read at macroaxis.com
Intellia insider trading alert for sale of common stock by Laura SeppLorenzino, EVP Chief Scientific Officer, on 5th of January 2024. This event was filed by Intellia Therapeutics Inc with SEC on 2024-01-05. Statement of changes in beneficial ownership - SEC Form 4. Laura SeppLorenzino currently serves as executive vice president chief scientific officer of Intellia Therapeutics

Cash Flow Correlation

Intellia Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Intellia Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Intellia Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Intellia Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Intellia Therapeutics Historical Investor Sentiment

Investor biases related to Intellia Therapeutics' public news can be used to forecast risks associated with an investment in Intellia. The trend in average sentiment can be used to explain how an investor holding Intellia can time the market purely based on public headlines and social activities around Intellia Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Intellia Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intellia Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Intellia Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Intellia Therapeutics.

Intellia Therapeutics Fundamental Analysis

We analyze Intellia Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intellia Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intellia Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Cash Flow From Operations

Cash Flow From Operations Comparative Analysis

Intellia Therapeutics is currently under evaluation in cash flow from operations category among its peers. Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Intellia Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Intellia Therapeutics stock to make a market-neutral strategy. Peer analysis of Intellia Therapeutics could also be used in its relative valuation, which is a method of valuing Intellia Therapeutics by comparing valuation metrics with similar companies.

Peers

Intellia Therapeutics Related Equities

VRTXVertex Pharmaceuticals   0.65   
8.0%
EDITEditas Medicine   0.81   
10.0%
CRSPCrispr Therapeutics   2.26   
29.0%
FATEFate Therapeutics   2.41   
31.0%
PRMEPrime Medicine,   3.06   
40.0%
VERVVerve Therapeutics   4.44   
58.0%
CRBUCaribou Biosciences   4.71   
61.0%
BEAMBeam Therapeutics   5.92   
77.0%
DNAGinkgo Bioworks   6.46   
84.0%
SANASana Biotechnology   7.65   
100.0%

Complementary Tools for Intellia Stock analysis

When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Transaction History
View history of all your transactions and understand their impact on performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Fundamental Analysis
View fundamental data based on most recent published financial statements